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“Every 11mmol/mol reduction in HbA1c 
delays the onset and slows the progression 
of  micro-vascular complications”   
(The Diabetes Control and Complications Trial) 1   
  
In 2013 we implemented a structural 
educational pathway for insulin pump 
initiation in NHS Dumfries and Galloway.  
 
We would like to determine the impact of 
insulin pump therapy following the insulin 
pump pathway on glycaemic control, total 
daily dose (TDD) of insulin, weight, rate of 
severe hypoglycaemia and diabetic 
ketoacidosis (DKA).  
  
  
 
Introduction 
In 2013 all insulin pump initiations were 
commenced following the insulin pump 
pathway. Data collection forms were 
completed prospectively for each patient at 
baseline, 6 and 12 months scheduled 
reviews. 
 
Outcomes included measures of HbA1c, 
weight, TDD from diasend, and incidences of 
severe hypoglycaemia and DKA from self 
reporting and hospital records. 
 
 
 
By January 2015 a total of 23 patients on 
insulin pump therapy completed the insulin  
pump pathway for 12 months.   
 
 
 
 
 Glycaemic Control 
❖ Mean HbA1c reduced from 76.2mmol/mol 
to 62.1mmol/mol at 12 months (p<0.005)   
❖ Mean reduction in HbA1c at 12 months 
was 16.1mmol/mol  
❖ HbA1c range changed over 12 months:-  
 
 
 
 
 
 
 
 
 
 
 
(See Figure below)   
  
Total Daily Dose of Insulin  
❖ The mean TDD of insulin reduced from         
61.8 units/day to 47.5 units/day(p=0.021)  
  
Weight 
❖ No significant weight change during the 
12 months  (p=0.400) 
❖ Mean reduction in weight was 3.1kg at 12 
months   
❖ Mean weight gain was 4.0kg at 12 months  
  
Severe Hypoglycaemia 
❖ No reported severe hypoglycaemia during 
the 12 month period  
  
Diabetic Ketoacidosis 
❖ No cases of DKA over the 12 months of 
commencing insulin pump therapy 
  
 
❖ Insulin pump and consumables are more 
expensive at £1091 per year more than 
MDI3    
 The Insulin pump offers the opportunity for 
cost benefits through:-  
 reduction in total daily insulin, 
reduction in hospital admission and 
outpatient contacts  
❖ The complications of diabetes increase 
 cost to the NHS five fold 2  
 Our data would support a reduction in long 
term complications with improved HbA1c  
❖ Total cost to treat someone with type 1 
diabetes in hospital  following a severe 
hypoglycaemic event  - £8874   
 Our data showed no evidence of severe 
hypoglycaemia  
  
 
Results Cost Saving 
Methods 
References 
Conclusion  
❖ Significant and sustained improvement in 
glycaemic control  
❖ Long term cost savings as insulin pump 
therapy can reduce HbA1c significantly 
hence reduce new and reduce the 
worsening of the existing micro-vascular  
conditions 
❖ Reduction in TDD of insulin  
❖ No increase in severe hypoglycaemia or 
hospitalisation with DKA  
❖ These benefits will allow people to be 
more productive for longer and reduce  
sickness absence 
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